查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584678

中樞神經系統治療市場：按疾病、藥物類型、給藥途徑、最終用戶分類 - 全球預測 2025-2030

Central Nervous System Therapeutics Market by Disorders (Epileptic Disorders, Neurodegenerative Diseases, Pain Management), Drug Type (Biologics, Small Molecules), Route of Administration, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

中樞神經系統治療市場2023年估值為1,338.3億美元，預計2024年將達1,431.1億美元，複合年成長率為7.24%，到2030年將達2,184.5億美元，預計將達到1美元。

中樞神經系統（CNS）治療市場包括針對神經系統疾病和疾病的多種治療方法，例如阿茲海默症、帕金森氏症、多發性硬化症和憂鬱症。由於人口老化、意識提高和醫療保健普及，神經系統疾病的盛行率不斷上升，推動了該市場的發展。這些疾病造成的巨大社會和經濟負擔強調了對中樞神經系統治療的需求，因此創新的治療選擇和改善患者的治療結果至關重要。應用多種多樣，包括藥物、基因和細胞療法，以及針對急性和慢性中樞神經系統疾病的創新遞送系統。主要最終用戶包括醫院、診所和研究機構。市場成長受到藥物輸送技術的進步、診斷技術的改進以及新型生技藥品的湧入的影響。尋求個人化醫療的機會比比皆是，重點是基因組學來創造標靶治療。研究和開發的合作、在藥物發現中使用人工智慧以及孤兒藥指定等監管激勵措施是利用新興機會的潛在途徑。然而，該市場面臨研發成本高、監管環境嚴格以及基礎設施障礙導致滲透新興地區的挑戰等限制。此外，缺乏預測模型和系統以及穿過血腦障壁的困難仍然是持續存在的挑戰。為了解決這些問題，生物標記的創新、改進的臨床試驗設計和腦支架技術可以帶來改變。中樞神經系統治療市場的動態、高風險、高回報性質需要持續創新和敏捷性。鼓勵公司投資合作研究，培養策略夥伴關係，利用技術進步，同時應對監管和營運挑戰。透過專注於全面的患者照護解決方案並利用數位健康技術，我們相信我們可以在這個不斷發展的環境中創造永續的競爭優勢。

主要市場統計
基準年[2023] 1338.3億美元
預測年份 [2024] 1431.1億美元
預測年份 [2030] 2184.5億美元
複合年成長率（%） 7.24%

市場動態：快速發展的中樞神經系統治療市場的關鍵市場洞察

供需的動態交互作用正在改變中樞神經系統治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加和神經退化性疾病盛行率
    • 政府對神經系統疾病研究的措施和資助
  • 市場限制因素
    • 與中樞神經系統疾病相關的產品案例增加
  • 市場機會
    • 投資神經退化性疾病的基因編輯技術與幹細胞研究
    • 使用奈米材料創新藥物配方的可能性
  • 市場挑戰
    • 中樞神經系統疾病複雜且難以穿越血腦障壁

波特五力：駕馭中樞神經系統藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對中樞神經系統治療市場的外部影響

外部宏觀環境因素在塑造中樞神經系統治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解中樞神經系統治療市場的競爭狀況

中樞神經系統治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣中樞神經系統治療市場供應商的績效評估

FPNV定位矩陣是評估中樞神經系統治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃中樞神經系統治療市場的成功之路

對於希望加強在全球市場的影響力的公司來說，中樞神經系統藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口的增加和神經退化性疾病的傳播
      • 實施政府措施及資助神經系統疾病研究
    • 抑制因素
      • 與中樞神經系統藥物相關的產品召回增加
    • 機會
      • 投資神經退化性疾病的基因編輯技術與幹細胞研究
      • 奈米材料在創新藥物配方中的潛在用途
    • 任務
      • 中樞神經系統疾病複雜且難以穿越血腦障壁
  • 市場區隔分析
    • 疾病：癲癇盛行率不斷上升，醫療需求未被滿足
    • 藥物類型：用於特異性和強效治療的創新生物製藥
    • 給藥途徑：由於其長效配方，注射劑是優選的。
    • 最終用戶：醫院對用於即時干涉的中樞神經系統療法有巨大的需求。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章中樞神經系統治療藥物市場秩序混亂

  • 癲癇症
    • 癲癇
    • 癲癇症
  • 神經退化性疾病
    • 阿茲海默症
    • 肌萎縮側索硬化症
    • 多發性硬化症
    • 帕金森氏症
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛
    • 神經病變疼痛
  • 精神疾病
    • 焦慮症
    • 躁鬱症
    • 憂鬱症
    • 思覺失調症

第7章依藥物類型分類的中樞神經系統治療藥物市場

  • 生物製藥
    • 基因治療
    • 單株抗體
    • 胜肽
    • 幹細胞療法
  • 小分子

第8章中樞神經系統治療市場：依給藥途徑

  • 可注射的
    • 肌肉注射
    • 靜脈
    • 皮下的
  • 口服
  • 經皮的

第9章中樞神經系統治療市場：依最終用戶分類

  • 醫院
  • 調查機構
  • 專科診所

第10章北美和南美中樞神經系統治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區中樞神經系統治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲中樞神經系統治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Amneal Pharmaceuticals 獲得 FDA核准CREXONT 增強帕金森氏症治療
    • Asen Neuron 獲得 1 億美元資金用於開發神經退化性疾病治療藥物 ASN51
    • 禮來公司的 Xanra 獲得 FDA核准用於阿茲海默症的早期治療
    • 羅氏與 Acidian Therapeutics 合作開發針對神經系統疾病的創新 RNA治療方法
    • Voyager Therapeutics 開始阿茲海默症藥物 VY-TAU01 的 1a 期試驗
    • Supernus Pharmaceuticals接受FDA 關於 SPN-830 的完整回覆信
    • 賽諾菲印度公司與 Cipla 合作，加強中樞神經系統治療藥物的分銷和推廣，以改善患者的治療效果。
    • Engrail Therapeutics 獲得 1.57 億美元 B 輪資金籌措，以推進非成癮性中樞神經系統療法並擴大戰略夥伴關係
    • Myrobalan Therapeutics 獲得 2,400 萬美元 A 輪資金籌措，以推進中樞神經系統治療
    • 艾伯維 (AbbVie) 在歐盟推出 Produodopa，這是一種革命性的 24 小時皮下輸注療法，用於治療進行性帕金森氏症
    • 4D Molecular Therapeutics 和 Arbor Biotechnologies 合作推進中樞神經系統疾病的創新基因療法
    • MapLight Therapeutics 獲得 2.25 億美元 C 輪資金籌措，以推進中樞神經系統治療
    • Pharmanovia 收購賽諾菲 11 個 CNS 品牌，擴大神經科產品組合
    • 諾華以 5 億美元收購專注於 siRNA 的 DTx Pharma，加強神經科學產品線
    • Neurocrine Biosciences 與 Voyager Therapeutics 合作價值 1.75 億美元的基因療法交易
  • 戰略分析和建議
    • F.霍夫曼拉羅氏股份公司
    • 百時美施貴寶公司
    • 羽扇豆有限公司
    • 艾伯維公司

公司名單

  • AbbVie Inc.
  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Acorda Therapeutics, Inc.
  • Alkermes PLC
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cassava Sciences, Inc.
  • Cipla Limited
  • CNS Pharmaceuticals, Inc.
  • Denali Therapeutics Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Ipsen SA
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • MapLight Therapeutics, Inc.
  • Merck KGaA
  • Minerva Neurosciences, Inc.
  • Neuraxpharm
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co Ltd
  • Pfizer Inc.
  • Polpharma Biologics SA
  • Rapport Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Supernus Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • TauRx Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-02026C4C9A19

The Central Nervous System Therapeutics Market was valued at USD 133.83 billion in 2023, expected to reach USD 143.11 billion in 2024, and is projected to grow at a CAGR of 7.24%, to USD 218.45 billion by 2030.

The Central Nervous System (CNS) Therapeutics market encompasses a broad range of treatments targeting neurological disorders and diseases, including Alzheimer's, Parkinson's, multiple sclerosis, and depression. This market is driven by the increasing prevalence of neurological disorders due to aging populations, rising awareness, and expanding healthcare access. The necessity for CNS therapeutics is underscored by the significant social and economic burden posed by these diseases, making innovative treatment options and improved patient outcomes critical. Applications span across pharmaceuticals, gene and cell therapies, and innovative delivery systems, catering to both acute and chronic aspects of CNS disorders. Key end-users include hospitals, clinics, and research institutions. Market growth is influenced by advancements in drug delivery technologies, improved diagnostic techniques, and an influx of novel biologics. Opportunities abound in the exploration of personalized medicine, with a focus on genomics to create targeted therapies. Collaborative efforts in R&D, artificial intelligence utilization for drug discovery, and regulatory incentives like orphan drug designation are potential routes to capitalize on burgeoning opportunities. However, the market faces limitations such as significant R&D costs, stringent regulatory landscapes, and challenges in penetrating developing regions due to infrastructure hurdles. The scarcity of predictive model systems and difficulty in crossing the blood-brain barrier remain persistent challenges. To address these, innovation in biomarkers, improved clinical trial designs, and brain scaffold technologies could be transformative. The nature of the CNS therapeutics market is dynamic, with a high-risk, high-reward profile demanding continuous innovation and agility. Companies are advised to invest in collaborative research, foster strategic partnerships, and leverage technological advancements while navigating the regulatory and operational challenges. Focusing on comprehensive patient care solutions and leveraging digital health technologies could create a sustainable competitive edge in this evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 133.83 billion
Estimated Year [2024] USD 143.11 billion
Forecast Year [2030] USD 218.45 billion
CAGR (%) 7.24%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Central Nervous System Therapeutics Market

The Central Nervous System Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing elderly population and the prevalence of neurodegenerative disorders
    • Implementation of government initiatives & funding for research on neurological disorders
  • Market Restraints
    • Rising cases of product recall associated with the CNS drugs
  • Market Opportunities
    • Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
    • Potential utilization of nanomaterials for innovative drug formulation
  • Market Challenges
    • Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier

Porter's Five Forces: A Strategic Tool for Navigating the Central Nervous System Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Central Nervous System Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Central Nervous System Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Central Nervous System Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Central Nervous System Therapeutics Market

A detailed market share analysis in the Central Nervous System Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Central Nervous System Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Central Nervous System Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Central Nervous System Therapeutics Market

A strategic analysis of the Central Nervous System Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Central Nervous System Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Acorda Therapeutics, Inc., Alkermes PLC, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cassava Sciences, Inc., Cipla Limited, CNS Pharmaceuticals, Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, H. Lundbeck A/S, Intra-Cellular Therapies, Inc., Ipsen S.A., Johnson & Johnson Services, Inc., Lupin Limited, MapLight Therapeutics, Inc., Merck KGaA, Minerva Neurosciences, Inc., Neuraxpharm, Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co Ltd, Pfizer Inc., Polpharma Biologics S.A., Rapport Therapeutics, Inc., Sage Therapeutics, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Central Nervous System Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disorders, market is studied across Epileptic Disorders, Neurodegenerative Diseases, Pain Management, and Psychiatric Disorders. The Epileptic Disorders is further studied across Epilepsy and Seizure Disorders. The Neurodegenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Pain Management is further studied across Acute Pain, Chronic Pain, and Neuropathic Pain. The Psychiatric Disorders is further studied across Anxiety Disorders, Bipolar Disorder, Depression, and Schizophrenia.
  • Based on Drug Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Gene Therapies, Monoclonal Antibodies, Peptides, and Stem Cell Therapies.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.
  • Based on End-Users, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing elderly population and the prevalence of neurodegenerative disorders
      • 5.1.1.2. Implementation of government initiatives & funding for research on neurological disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Rising cases of product recall associated with the CNS drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Investment in gene-editing technologies and stem cell research for neurodegenerative diseases
      • 5.1.3.2. Potential utilization of nanomaterials for innovative drug formulation
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities of CNS disorders coupled with difficulty in crossing the blood-brain barrier
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disorders: Increasing epileptic disorder prevalence and significant unmet medical needs
    • 5.2.2. Drug Type: Innovative biologics for particular and potent treatments
    • 5.2.3. Route of Administration: High preference for injectable routes owing to their long-acting formulations
    • 5.2.4. End-Users: Significant demand for CNS therapeutics in hospitals for immediate interventions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Central Nervous System Therapeutics Market, by Disorders

  • 6.1. Introduction
  • 6.2. Epileptic Disorders
    • 6.2.1. Epilepsy
    • 6.2.2. Seizure Disorders
  • 6.3. Neurodegenerative Diseases
    • 6.3.1. Alzheimer's Disease
    • 6.3.2. Amyotrophic Lateral Sclerosis
    • 6.3.3. Multiple Sclerosis
    • 6.3.4. Parkinson's Disease
  • 6.4. Pain Management
    • 6.4.1. Acute Pain
    • 6.4.2. Chronic Pain
    • 6.4.3. Neuropathic Pain
  • 6.5. Psychiatric Disorders
    • 6.5.1. Anxiety Disorders
    • 6.5.2. Bipolar Disorder
    • 6.5.3. Depression
    • 6.5.4. Schizophrenia

7. Central Nervous System Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Gene Therapies
    • 7.2.2. Monoclonal Antibodies
    • 7.2.3. Peptides
    • 7.2.4. Stem Cell Therapies
  • 7.3. Small Molecules

8. Central Nervous System Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Oral
  • 8.4. Transdermal

9. Central Nervous System Therapeutics Market, by End-Users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes
  • 9.4. Specialty Clinics

10. Americas Central Nervous System Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Central Nervous System Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Amneal Pharmaceuticals receives FDA approval for CREXONT to enhance Parkinson's therapy
    • 13.3.2. Asceneuron secures USD 100M to advance ASN51 for neurodegenerative diseases
    • 13.3.3. Eli Lilly's Kisunla receives FDA approval for early Alzheimer's treatment
    • 13.3.4. Roche and Ascidian Therapeutics join forces to develop innovative RNA therapies for neurological diseases
    • 13.3.5. Voyager Therapeutics initiates Phase 1a trial of VY-TAU01 for Alzheimer's
    • 13.3.6. Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830
    • 13.3.7. Sanofi India partners with Cipla to enhance distribution and promotion of CNS therapeutics to improve patient outcomes
    • 13.3.8. Engrail Therapeutics secures USD 157M Series B funding to advance non-addictive CNS therapies and expand strategic partnerships
    • 13.3.9. Myrobalan Therapeutics secures USD 24 million in Series A funding to advance CNS treatments
    • 13.3.10. AbbVie launches Produodopa, a groundbreaking 24-hour subcutaneous infusion therapy for advanced Parkinson's in the EU
    • 13.3.11. 4D Molecular Therapeutics and Arbor Biotechnologies partner to advance innovative genetic therapies for CNS disorders
    • 13.3.12. MapLight Therapeutics secures USD 225 million Series C funding to advance CNS therapies
    • 13.3.13. Pharmanovia expands neurology portfolio by acquiring 11 CNS brands from Sanofi
    • 13.3.14. Novartis strengthens neuroscience pipeline with USD 500M acquisition of siRNA-focused DTx Pharma
    • 13.3.15. Neurocrine Biosciences collaborates with Voyager Therapeutics on USD 175M gene therapy deal
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. F. Hoffmann-La Roche AG
    • 13.4.2. Bristol-Myers Squibb Company
    • 13.4.3. Lupin Limited
    • 13.4.4. AbbVie Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AC Immune SA
  • 3. Acadia Pharmaceuticals Inc.
  • 4. Acorda Therapeutics, Inc.
  • 5. Alkermes PLC
  • 6. Amgen Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. Biogen Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. C.H. Boehringer Sohn AG & Co. KG
  • 12. Cassava Sciences, Inc.
  • 13. Cipla Limited
  • 14. CNS Pharmaceuticals, Inc.
  • 15. Denali Therapeutics Inc.
  • 16. Eisai Co. Ltd.
  • 17. Eli Lilly and Company
  • 18. F. Hoffmann-La Roche AG
  • 19. GlaxoSmithKline PLC
  • 20. H. Lundbeck A/S
  • 21. Intra-Cellular Therapies, Inc.
  • 22. Ipsen S.A.
  • 23. Johnson & Johnson Services, Inc.
  • 24. Lupin Limited
  • 25. MapLight Therapeutics, Inc.
  • 26. Merck KGaA
  • 27. Minerva Neurosciences, Inc.
  • 28. Neuraxpharm
  • 29. Novartis AG
  • 30. Novo Nordisk A/S
  • 31. Otsuka Holdings Co Ltd
  • 32. Pfizer Inc.
  • 33. Polpharma Biologics S.A.
  • 34. Rapport Therapeutics, Inc.
  • 35. Sage Therapeutics, Inc.
  • 36. Sanofi S.A.
  • 37. Sun Pharmaceutical Industries Limited
  • 38. Supernus Pharmaceuticals, Inc.
  • 39. Takeda Pharmaceutical Company Limited
  • 40. TauRx Pharmaceuticals Ltd
  • 41. Teva Pharmaceutical Industries Ltd.
  • 42. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SEIZURE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPTIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD